We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lynch Syndrome Screening by IHC Leads to Mutation Studies

By LabMedica International staff writers
Posted on 24 Oct 2019
Print article
Image: A and B, Mucinous adenocarcinoma of colon and indeterminate PMS2 immunohistochemistry staining. C and D, Poorly differentiated carcinoma of colon and indeterminate MLH1 staining. E and F, Endometrial carcinoma and focal MSH6 staining (Photo courtesy of University of Texas Southwestern Medical Center).
Image: A and B, Mucinous adenocarcinoma of colon and indeterminate PMS2 immunohistochemistry staining. C and D, Poorly differentiated carcinoma of colon and indeterminate MLH1 staining. E and F, Endometrial carcinoma and focal MSH6 staining (Photo courtesy of University of Texas Southwestern Medical Center).
Lynch syndrome or hereditary nonpolyposis colorectal cancer is an autosomal dominant genetic condition that is associated with a high risk of colon cancer, as well as other cancers including endometrial cancer, ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin.

Immunohistochemical expression of mismatch repair (MMR) protein is a well-accepted method for routine screening for Lynch syndrome (LS) with relatively high sensitivity and specificity. Occasionally, however, immunohistochemistry (IHC) can yield an equivocal result with poor reproducibility and the potential for misdiagnosis.

A pathologist and a geneticist from the University of Texas Southwestern Medical Center (Dallas, TX, USA) retrospectively analyzed the data on MMR (MLH1, PMS2, MSH2, and MSH6) IHC results from their database of 479 patients with colorectal cancer (CRC) and endometrial cancer (EC) who were screened for LS between September 2011 and August 2013. Mismatch repair protein IHC was performed prospectively in all patients with a tissue diagnosis of CRC or EC before 70 and 50 years of age, respectively.

Semi-quantitative scoring of MMR IHC was performed by image analysis in 479 cases, of which 380 were colorectal and 99 endometrial cancers. Scores of 10% or more, less than 10%, and 0% were used as cutoffs for retained, indeterminate, and loss of expression, respectively. Negative and indeterminate IHC results were confirmed by mutational studies. The automated cell imaging system consisted of an automated robotic bright-field microscope module and a Windows NT–based software interface that digitizes the IHC-stained slide, and digital images were displayed on a computer screen and analyzed by proprietary software. Confirmatory germline testing was initiated after counseling the patients about the abnormal IHC results and obtaining their permission for further genetic testing.

The scientists reported that 418/479 cases (87.2%) were reported as retained expression, 45 (9.3%) as loss of expression, and 16 (3.3%) as indeterminate expression. Fifteen of 45 (33.3%) and eight of 16 (50%) with loss and indeterminate expression, respectively, were found to have Lynch syndrome by germline studies. The overall frequency of Lynch syndrome in the patient population was 4.8% (23/479), and 34.7% of these (8/23) were associated with indeterminate IHC expression. In the indeterminate group, MLH1 germline mutation was the most frequent (6/13; 46.2%), followed by MSH6 (4/13; 30.7%).

The authors concluded that their findings provided further evidence that indeterminate IHC should be further investigated for possible MMR germline mutation. Guidelines for interpretation of MMR IHC and the establishment of more objective criteria for defining indeterminate results are important to improve the sensitivity and specificity of the IHC assay. The study was published in the October 2019 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
University of Texas Southwestern Medical Center

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.